These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 34527683)

  • 21. [Risk factors associated with the progression of chronic HBV infection in patients with normal ALT].
    Wei L; Li H; Hu P
    Zhonghua Gan Zang Bing Za Zhi; 2020 Dec; 28(12):995-998. PubMed ID: 34865345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis and treatment of chronic hepatitis B: an update.
    Morgan M; Park W; Keeffe EB
    Minerva Gastroenterol Dietol; 2007 Mar; 53(1):25-41. PubMed ID: 17415343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New insights into immunotolerant phase of chronic hepatitis B virus infection].
    Duan MH; Liu XE; Zhuang H
    Zhonghua Gan Zang Bing Za Zhi; 2021 Mar; 29(3):284-288. PubMed ID: 33902199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic hepatitis B: the demise of the 'inactive carrier' phase.
    Koffas A; Kumar M; Gill US; Jindal A; Kennedy PTF; Sarin SK
    Hepatol Int; 2021 Apr; 15(2):290-300. PubMed ID: 33638770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B.
    Duan M; Chi X; Xiao H; Liu X; Zhuang H
    Hepatol Int; 2021 Apr; 15(2):318-327. PubMed ID: 33638049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B.
    Kim HL; Kim GA; Park JA; Kang HR; Lee EK; Lim YS
    Gut; 2021 Nov; 70(11):2172-2182. PubMed ID: 33239344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase.
    Lee HA; Lee HW; Kim IH; Park SY; Sinn DH; Yu JH; Seo YS; Um SH; Lee JI; Lee KS; Lee CH; Tak WY; Kweon YO; Kang W; Paik YH; Lee JW; Suh SJ; Jung YK; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Yim HJ; Kim SU
    Aliment Pharmacol Ther; 2020 Jul; 52(1):196-204. PubMed ID: 32452564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B.
    Yuen L; Revill PA; Rosenberg G; Wagner J; Littlejohn M; Bayliss J; Jackson K; Tan SK; Gaggar A; Kitrinos K; Subramanian M; Gane E; Chan HLY; Li X; Bowden S; Locarnini S; Thompson A
    J Viral Hepat; 2020 Oct; 27(10):1061-1070. PubMed ID: 32384174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reasons to consider early treatment in chronic hepatitis B patients.
    Koffas A; Petersen J; Kennedy PT
    Antiviral Res; 2020 May; 177():104783. PubMed ID: 32217150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy.
    Sun Y; Wu X; Zhou J; Meng T; Wang B; Chen S; Liu H; Wang T; Zhao X; Wu S; Kong Y; Ou X; Wee A; Theise ND; Qiu C; Zhang W; Lu F; Jia J; You H
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2582-2591.e6. PubMed ID: 32147592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conservative Evolution of Hepatitis B Virus Precore and Core Gene During Immune Tolerant Phase in Intrafamilial Transmission.
    Luo Y; Zhang L; Dai Y; Hu Y; Xu B; Zhou YH
    Virol Sin; 2020 Aug; 35(4):388-397. PubMed ID: 32124248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy.
    Nguyen MH; Wong G; Gane E; Kao JH; Dusheiko G
    Clin Microbiol Rev; 2020 Mar; 33(2):. PubMed ID: 32102898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The guidelines of prevention and treatment for chronic hepatitis B (2019 version)].
    ;
    Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):938-961. PubMed ID: 31941257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HBV-Induced Immune Imbalance in the Development of HCC.
    Chen Y; Tian Z
    Front Immunol; 2019; 10():2048. PubMed ID: 31507621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus.
    Hou J; Cui F; Ding Y; Dou X; Duan Z; Han G; Jia J; Mao Q; Li J; Li Z; Liu Z; Wei L; Xie Q; Yang X; Zhang H; Zhuang H
    Clin Gastroenterol Hepatol; 2019 Sep; 17(10):1929-1936.e1. PubMed ID: 30312789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
    Terrault NA; Lok ASF; McMahon BJ; Chang KM; Hwang JP; Jonas MM; Brown RS; Bzowej NH; Wong JB
    Hepatology; 2018 Apr; 67(4):1560-1599. PubMed ID: 29405329
    [No Abstract]   [Full Text] [Related]  

  • 37. Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend.
    Wong GL
    Clin Mol Hepatol; 2018 Jun; 24(2):108-113. PubMed ID: 29353469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
    Kim GA; Lim YS; Han S; Choi J; Shim JH; Kim KM; Lee HC; Lee YS
    Gut; 2018 May; 67(5):945-952. PubMed ID: 29055908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
    ;
    J Hepatol; 2017 Aug; 67(2):370-398. PubMed ID: 28427875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment.
    Kim JH; Sinn DH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Hepatology; 2017 Aug; 66(2):335-343. PubMed ID: 28012257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.